Management of Patients with Diabetic Macular Edema Switched from Dexamethasone Intravitreal Implant to Fluocinolone Acetonide Intravitreal Implant
| dc.rights.license | open | en_US |
| dc.contributor.author | BAILLIF, Stephanie | |
| dc.contributor.author | STACCINI, Pascal | |
| dc.contributor.author | WEBER, Michel | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | DELYFER, Marie-Noelle | |
| dc.contributor.author | LE MER, Yannick | |
| dc.contributor.author | GUALINO, Vincent | |
| dc.contributor.author | COLLOT, Laurence | |
| dc.contributor.author | MERITE, Pierre-Yves | |
| dc.contributor.author | CREUZOT-GARCHER, Catherine | |
| dc.contributor.author | KODJIKIAN, Laurent | |
| dc.contributor.author | MASSIN, Pascale | |
| dc.date.accessioned | 2022-12-15T08:52:23Z | |
| dc.date.available | 2022-12-15T08:52:23Z | |
| dc.date.issued | 2022-11-05 | |
| dc.identifier.issn | 1999-4923 (Print) 1999-4923 (Linking) | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/171526 | |
| dc.description.abstractEn | To assess anatomical and functional outcomes after switching from dexamethasone implant (DEXi) to fluocinolone acetonide implant (FAci) in 113 diabetic macular edema eyes, a multicentric retrospective observational study was conducted. Seventy-five eyes (73.5%) were switched 1-8 weeks after their last DEXi. The mean best-corrected visual acuity improved to 59.8 letters at month 4 and remained stable during the follow-up. The mean central macular thickness (CMT) significantly decreased during the follow-up, with a minimum of 320.9 μm at month 3. The baseline CMT was higher in eyes that received the last DEXi >8 weeks versus <8 weeks before the first FAci (p < 0.021). After FAci injection, additional treatments were needed in 37 (32.7%) eyes. A longer diabetes duration (p = 0.009), a longer time between the last DEXi and the first FAci (p = 0.035), and a high baseline CMT (p = 0.003) were risk factors for additional treatments. The mean intraocular pressure was <19 mmHg at all timepoints, with no difference between eyes receiving the last DEXi ≤8 weeks or >8 weeks before the switch. Switching from DEXi to FAci in DME is effective and safe. A short time between the last DEXi and the first FAci reduced CMT fluctuations and the need for early additional treatments. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
| dc.subject.en | Diabetic macular edema | |
| dc.subject.en | Dexamethasone implant | |
| dc.subject.en | Fluocinolone acetonide implant | |
| dc.subject.en | Intravitreal therapy | |
| dc.title.en | Management of Patients with Diabetic Macular Edema Switched from Dexamethasone Intravitreal Implant to Fluocinolone Acetonide Intravitreal Implant | |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.3390/pharmaceutics14112391 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 36365209 | en_US |
| bordeaux.journal | Pharmaceutics | en_US |
| bordeaux.volume | 14 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.issue | 11 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | LEHA_BPH | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.export | false | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Pharmaceutics&rft.date=2022-11-05&rft.volume=14&rft.issue=11&rft.eissn=1999-4923%20(Print)%201999-4923%20(Linking)&rft.issn=1999-4923%20(Print)%201999-4923%20(Linking)&rft.au=BAILLIF,%20Stephanie&STACCINI,%20Pascal&WEBER,%20Michel&DELYFER,%20Marie-Noelle&LE%20MER,%20Yannick&rft.genre=article |
